Oct 26th 2012 - Edison Investment Research today published a report on Clavis Pharma entitled "Poised For A LEAP Forward". In summary, the report says:
Q3 results show Clavis remains on track clinically and financially, as the key LEAP Q4 data announcement looms. The pivotal CP-4126 trial might allow a 2013 FDA submission by the global partner, Clovis. Commercially, Clavis is signalling that a successful LEAP outcome will cause it to trigger its EU co-marketing option, costing $20-25m, equalling the regulatory filing milestone. The important, but less crucial, elacytarabine data in refractory/relapsed AML is due Q113. Elacytarabine may be partnered in the US if successful and marketed directly in Europe.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »